Identification of BCR-ABL point mutations conferring resistance to the Abl kinase inhibitor AMN107 (nilotinib) by a random mutagenesis study.
about
AMN107 (nilotinib): a novel and selective inhibitor of BCR-ABLTargeting Bcr–Abl by combining allosteric with ATP-binding-site inhibitorsMechanisms of drug resistance in kinases.Reversible resistance induced by FLT3 inhibition: a novel resistance mechanism in mutant FLT3-expressing cellsImpact of additional chromosomal aberrations and BCR-ABL kinase domain mutations on the response to nilotinib in Philadelphia chromosome-positive chronic myeloid leukemia.Oncogenic JAK1 and JAK2-activating mutations resistant to ATP-competitive inhibitors.Predictive factors for outcome and response in patients treated with second-generation tyrosine kinase inhibitors for chronic myeloid leukemia in chronic phase after imatinib failure.Critical roles for mTORC2- and rapamycin-insensitive mTORC1-complexes in growth and survival of BCR-ABL-expressing leukemic cells.Kinase domain mutations confer resistance to novel inhibitors targeting JAK2V617F in myeloproliferative neoplasms.Nilotinib for the treatment of chronic myeloid leukemia: An evidence-based reviewLong-term outcome of patients with chronic myeloid leukemia treated with second-generation tyrosine kinase inhibitors after imatinib failure is predicted by the in vitro sensitivity of BCR-ABL kinase domain mutations.Development and targeted use of nilotinib in chronic myeloid leukemia.Critical appraisal of nilotinib in frontline treatment of chronic myeloid leukemia.Regulatory effects of sestrin 3 (SESN3) in BCR-ABL expressing cellsSimultaneous determination of the novel tyrosine kinase inhibitor meditinib and its active metabolite demethylation meditinib in monkey plasma by liquid chromatography-tandem mass spectrometry and its application to pharmacokinetic studies.Beneficial effects of combining nilotinib and imatinib in preclinical models of BCR-ABL+ leukemias.Acquired resistance to drugs targeting receptor tyrosine kinasesNilotinib treatment in mouse models of P190 Bcr/Abl lymphoblastic leukemia.ABL kinase domain mutations in patients with chronic myeloid leukemia in Jordan.SGX393 inhibits the CML mutant Bcr-AblT315I and preempts in vitro resistance when combined with nilotinib or dasatinib.BCR-ABL1 compound mutations in tyrosine kinase inhibitor-resistant CML: frequency and clonal relationshipsTherapeutic options for chronic myeloid leukemia: focus on imatinib (Glivec, Gleevectrade mark).Laboratory practice guidelines for detecting and reporting BCR-ABL drug resistance mutations in chronic myelogenous leukemia and acute lymphoblastic leukemia: a report of the Association for Molecular Pathology.Targeted therapy in chronic myeloid leukemia.Emerging therapeutic strategies for targeting chronic myeloid leukemia stem cellsTargeting survival cascades induced by activation of Ras/Raf/MEK/ERK, PI3K/PTEN/Akt/mTOR and Jak/STAT pathways for effective leukemia therapy.Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet.Impact of baseline BCR-ABL mutations on response to nilotinib in patients with chronic myeloid leukemia in chronic phaseA Convenient Cell Culture Model for CML Acquired Resistance Through BCR-ABL Mutations.Nilotinib: a phenylamino-pyrimidine derivative with activity against BCR-ABL, KIT and PDGFR kinases.Identification of mutations in TgMAPK1 of Toxoplasma gondii conferring resistance to 1NM-PP1.Class effects of tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia.Use of dasatinib and nilotinib in imatinib-resistant chronic myeloid leukemia: translating preclinical findings to clinical practice.Molecular techniques for the personalised management of patients with chronic myeloid leukaemia.Targeting the BCR-ABL tyrosine kinase in chronic myeloid leukemia as a model of rational drug design in cancer.The expanding role of nilotinib in chronic myeloid leukemia.Refining targeted therapies in chronic myeloid leukemia: development and application of nilotinib, a step beyond imatinib.Vemurafenib (PLX4032): an orally available inhibitor of mutated BRAF for the treatment of metastatic melanoma.BCR-ABL1 kinase domain mutations: methodology and clinical evaluation.Prognostic Significance of Treatment Response in CML in View of Current Recommendations for Treatment and Monitoring.
P2860
Q24651465-40AEE191-B110-4031-83D2-4FEE78AFAAEDQ27658951-227AC7AA-EF28-4189-8036-6CB68B62FD6AQ27692567-6DD8540F-2D81-4E59-9971-33D6310E63D4Q28477269-5282926D-36BB-41FE-A151-1F2C11441975Q33518973-456DC9C5-E1E9-4744-94AD-5B0A4E982BCDQ33843072-8F65B8A4-58BD-45A0-AA2A-80F80F484627Q33843731-1B5B7022-4517-4848-84D6-61A82900AC4CQ34004994-68F430D2-DC28-4629-9203-E4A166EEAE8DQ34021753-42204CCF-97C4-4C62-AF09-43ADA101FC2AQ34130343-000BC84D-9431-4820-AC93-66E641D6DBCEQ34293384-BB1D90AA-7AAB-4F75-8D29-CCDBD5FF40CAQ34613968-5E4ABEB9-7739-4781-94DC-A555AB68573DQ34894883-F53E25C6-A418-4906-A16C-116DDEA7F05FQ35048118-4AF6C780-CB94-48C6-91A6-2B07670E5DC7Q35548143-EBEC4ECA-14BE-435D-A3EF-506B3D6E63E8Q35642790-F6B72EBA-C428-42AC-BE78-2D2FC77C908EQ35823437-8287D31E-6C67-480C-9B9E-BFFED72B5223Q36316166-56C5732E-6D6C-42E2-AE43-7EBBB502A1C4Q36353183-979DF239-C23E-4DAE-BA5E-5AEEC074B8E7Q36535476-C39C4FF5-5ADF-47E0-9C1E-3A2D821E4654Q36542821-47BBAC52-B988-45E3-B6F8-4EF871160400Q36822880-101C5AA7-CEDA-46FA-A276-4B804F0D88ECQ37024667-BBE2A623-04D6-40A5-A2DF-E342747CBBF2Q37038914-BC88E542-6E13-49EF-B5CB-93EC2AA7A705Q37051682-94F14BD0-E39E-479E-A605-7B9FA14BC7E9Q37109225-FF38EA20-E6A0-4428-8EEE-4F9483E123E3Q37163550-59E0DE74-ABD2-462E-84A1-60AAE1ABFD9BQ37163834-8E835377-6089-4D10-A26C-BEE428EB184AQ37229516-714C7BEC-4527-4DFC-8845-AF0768911ECCQ37298638-70682298-EEBA-4E4E-AA24-5AA24EEE850BQ37390619-89CB8ED3-94A7-4CAF-9673-1FF88D74513BQ37498272-976456B4-2F28-4410-8FB8-EFC05F1A11C8Q37663655-BE3D9772-966A-434B-B47D-3AD6B057C09FQ37696776-20A6E7C0-F23D-4BAC-966A-ACD30A6E4D12Q37810070-AEC6BBFF-9508-4C8F-BF1F-6146E3B986DAQ37814411-07095B50-70B8-4FAC-97BE-643831FF8C14Q37815384-EB43DE6F-E9AB-44C8-BDDE-DD54BC35DDA7Q37949571-45AD7A98-AEEC-4EFF-930C-DD58ED43E5F1Q37974490-F7FD9AF4-64DA-4533-8E72-BBD91C0593F0Q38095956-ECB6E5AC-74F4-4E38-9430-2A52F9AA51A3
P2860
Identification of BCR-ABL point mutations conferring resistance to the Abl kinase inhibitor AMN107 (nilotinib) by a random mutagenesis study.
description
2007 nî lūn-bûn
@nan
2007 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
Identification of BCR-ABL poin ...... by a random mutagenesis study.
@ast
Identification of BCR-ABL poin ...... by a random mutagenesis study.
@en
type
label
Identification of BCR-ABL poin ...... by a random mutagenesis study.
@ast
Identification of BCR-ABL poin ...... by a random mutagenesis study.
@en
prefLabel
Identification of BCR-ABL poin ...... by a random mutagenesis study.
@ast
Identification of BCR-ABL poin ...... by a random mutagenesis study.
@en
P2093
P1433
P1476
Identification of BCR-ABL poin ...... by a random mutagenesis study.
@en
P2093
Arghya Ray
James D Griffin
Jürgen Mestan
Paul W Manley
Sandra W Cowan-Jacob
P304
P356
10.1182/BLOOD-2006-01-015347
P407
P577
2007-02-15T00:00:00Z